PMID- 17709267
OWN - NLM
STAT- MEDLINE
DCOM- 20080208
LR  - 20221207
IS  - 1096-6374 (Print)
IS  - 1096-6374 (Linking)
VI  - 17
IP  - 6
DP  - 2007 Dec
TI  - Insulin-like growth factor system gene expression in cervical scrapes from women 
      with squamous intraepithelial lesions and cervical cancer.
PG  - 492-9
AB  - BACKGROUND: There is ample evidence that the insulin-like growth factors (IGF) 
      system is involved in the development of several types of cancer. The aim of this 
      study was to evaluate the expression levels of IGF-I, IGF-II, IGF binding protein 
      3 (IGFBP-3) and IGF-I receptor (IGF-IR) in exfoliated cervical cells in cervical 
      carcinogenesis. METHODS: mRNA levels of IGF-I, IGF-II, IGFBP-3 and IGF-IR were 
      assessed by real-time PCR in 105 cervical scrapes obtained from 16 patients 
      diagnosed with low-grade squamous intraepithelial lesions (LSIL), 24 with 
      high-grade SIL (HSIL), 23 with cervical cancer, and 42 from controls with normal 
      Papanicolau (Pap) test. RESULTS: IGF-I mRNA levels were very low and no 
      significant differences were seen between control and other groups. IGF-II mRNA 
      levels were significantly lower in LSIL than in control group (median [arbitrary 
      units]: 0.38 vs. 2.42, P=0.006) but its expression in HSIL and cervical cancer 
      was similar to the one observed in controls. IGFBP-3 mRNA levels were 
      significantly lower in cancer than in controls (median [arbitrary units]: 0.43 
      vs. 0.73, P=0.03). We observed a decrease in IGF-IR gene expression as the SIL 
      degree increased (median for controls, LSIL, HSIL, and cervical carcinoma 
      [arbitrary units]: 31.24, 9.08, 8.95, and 3.56, respectively). IGF-IR mRNA levels 
      were significantly lower in HSIL and cervical cancer in comparison with controls 
      (P=0.043 and P<0.001, respectively). CONCLUSIONS: The present observations 
      suggest that a reduced expression of IGFBP-3 and IGF-IR can be associated with 
      progression to cervical cancer; the specific role played by the IGF-IR in this 
      process remains unclear.
FAU - Serrano, Martha-Lucia
AU  - Serrano ML
AD  - Grupo de Investigacion en Biologia del Cancer, Instituto Nacional de 
      Cancerologia, Bogota, Colombia.
FAU - Sanchez-Gomez, Myriam
AU  - Sanchez-Gomez M
FAU - Bravo, Maria-Mercedes
AU  - Bravo MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070820
PL  - Scotland
TA  - Growth Horm IGF Res
JT  - Growth hormone & IGF research : official journal of the Growth Hormone Research 
      Society and the International IGF Research Society
JID - 9814320
RN  - 0 (IGFBP3 protein, human)
RN  - 0 (Insulin-Like Growth Factor Binding Protein 3)
RN  - 0 (Insulin-Like Growth Factor Binding Proteins)
RN  - 0 (RNA, Messenger)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 67763-97-7 (Insulin-Like Growth Factor II)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Insulin-Like Growth Factor Binding Protein 3
MH  - Insulin-Like Growth Factor Binding Proteins/*genetics
MH  - Insulin-Like Growth Factor I/*genetics
MH  - Insulin-Like Growth Factor II/*genetics
MH  - Middle Aged
MH  - Neoplasms, Squamous Cell/chemistry/*genetics/pathology
MH  - RNA, Messenger/biosynthesis
MH  - Receptor, IGF Type 1/*genetics
MH  - Uterine Cervical Neoplasms/chemistry/*genetics/pathology
MH  - Vaginal Smears
MH  - Uterine Cervical Dysplasia/chemistry/*genetics/pathology
EDAT- 2007/08/22 09:00
MHDA- 2008/02/09 09:00
CRDT- 2007/08/22 09:00
PHST- 2007/04/04 00:00 [received]
PHST- 2007/06/27 00:00 [revised]
PHST- 2007/07/02 00:00 [accepted]
PHST- 2007/08/22 09:00 [pubmed]
PHST- 2008/02/09 09:00 [medline]
PHST- 2007/08/22 09:00 [entrez]
AID - S1096-6374(07)00090-1 [pii]
AID - 10.1016/j.ghir.2007.07.001 [doi]
PST - ppublish
SO  - Growth Horm IGF Res. 2007 Dec;17(6):492-9. doi: 10.1016/j.ghir.2007.07.001. Epub 
      2007 Aug 20.